Safety of MR liver specific contrast media

Bellin, Marie‐France; Webb, Judith A. W.; Molen, Aart J. van der; Thomsen, Henrik S.; Morcos, Sameh K.

doi:10.1007/s00330-004-2612-x

Cited by 42 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gd-EOB-DTPA is a hepatobiliary MRI contrast agent with high T1 relaxivity in the liver. It is cleared from the body by two elimination routes: receptor-specific uptake by the hepatocytes with subsequent biliary excretion and glomerular filtration in the kidneys with subsequent urinary excretion (13). Hepatobiliary elimination accounts for approximately 50% of the total elimination.…”

Section: Discussionmentioning

confidence: 99%

The T2-Shortening Effect of Gadolinium and the Optimal Conditions for Maximizing the CNR for Evaluating the Biliary System: a Phantom Study

et al. 2011

View full text Add to dashboard Cite

ObjectiveClear depiction of the common bile duct is important when evaluating neonatal cholestasis in order to differentiate biliary atresia from other diseases. During MR cholangiopancreatography, the T2-shortening effect of gadolinium can increase the contrast-to-noise ratio (CNR) of the bile duct and enhance its depiction. The purpose of this study was to confirm, by performing a phantom study, the T2-shortening effect of gadolinium, to evaluate the effect of different gadolinium chelates with different gadolinium concentrations and different magnetic field strengths for investigating the optimal combination of these conditions, and for identifying the maximum CNR for the evaluation of the biliary system.Materials and MethodsMR imaging using a T2-weighted single-shot fast spin echo sequence and T2 relaxometry was performed with a sponge phantom in a syringe tube. Two kinds of contrast agents (Gd-DTPA and Gd-EOB-DTPA) with different gadolinium concentrations were evaluated with 1.5T and 3T scanners. The signal intensities, the CNRs and the T2 relaxation time were analyzed.ResultsThe signal intensities significantly decreased as the gadolinium concentrations increased (p < 0.001) with both contrast agents. These signal intensities were higher on a 3T (p < 0.001) scanner. The CNRs were higher on a 1.5T (p < 0.001) scanner and they showed no significant change with different gadolinium concentrations. The T2 relaxation time also showed a negative correlation with the gadolinium concentrations (p < 0.001) and the CNRs showed decrease more with Gd-EOB-DTPA (versus Gd-DTPA; p < 0.001) on a 3T scanner (versus 1.5T; p < 0.001).ConclusionA T2-shortening effect of gadolinium exhibits a negative correlation with the gadolinium concentration for both the signal intensities and the T2 relaxation time. A higher CNR can be obtained with Gd-DTPA on a 1.5T MRI scanner.

show abstract

Section: Discussionmentioning

confidence: 99%

The T2-Shortening Effect of Gadolinium and the Optimal Conditions for Maximizing the CNR for Evaluating the Biliary System: a Phantom Study

et al. 2011

View full text Add to dashboard Cite

show abstract

“…12 We posit that the higher incidence of reactions observed with Gd-EOB-DTPA was attributable to its greater degree of protein binding than that of other Gdbased agents. 13 In addition, Gd-EOB-DTPA could be used to evaluate hepatocellular carcinoma and metastasis or other liver tumors because the backgrounds of these patients were different from those of patients who received the other 3 Gd-contrast agents (Gd-DTPA, Gd-DO3A, and Gd-DOTA), which were used for general clinical purposes related not only to oncological diseases but also to inflammatory, orthopedic, and cardiovascular diseases. In a review of clinical Phase II and III studies that summarized safety data on Gd-EOB-DTPA, 13 120 of 1,404 patients (8.5%) experienced one or more adverse effects.…”

Section: Discussionmentioning

confidence: 99%

“…13 In addition, Gd-EOB-DTPA could be used to evaluate hepatocellular carcinoma and metastasis or other liver tumors because the backgrounds of these patients were different from those of patients who received the other 3 Gd-contrast agents (Gd-DTPA, Gd-DO3A, and Gd-DOTA), which were used for general clinical purposes related not only to oncological diseases but also to inflammatory, orthopedic, and cardiovascular diseases. In a review of clinical Phase II and III studies that summarized safety data on Gd-EOB-DTPA, 13 120 of 1,404 patients (8.5%) experienced one or more adverse effects. The drug information sheets of Bayer Healthcare (available at http://www.info.pmda.go.jp/go/ pack/7290415G1020_1_07/) report that the rate of adverse effects of Gd-EOB-DTPA was 76/1755 (4.3%) for regulatory approval in Japan.…”

Section: Discussionmentioning

confidence: 99%

Incidence and Severity of Acute Adverse Reactions to Four Different Gadolinium-based MR Contrast Agents

et al. 2014

View full text Add to dashboard Cite

Purpose: Differences in acute adverse reactions to different gadolinium (Gd)-based contrast agents have not been thoroughly evaluated. We investigated the relationships among the incidence and severity of acute adverse reactions, backgrounds of patients, and 4 types of different Gd-based contrast agents (gadopentetate dimeglumine, gadoteridol, gadoterate meglumine, and gadoxetate disodium).Materials and Methods: We retrospectively reviewed the radiological records of 10,595 consecutive patients (4,343 female; 6,252 male; mean age, 63.8 « 14.0 years) who underwent contrast-enhanced magnetic resonance imaging between August 2006 and March 2011. Adverse reactions were classified as mild, moderate, and severe according to the definition of the American College of Radiology. The incidence of adverse reactions were compared on the basis of clinical characteristics and type, dose, and delivery methods of contrast agents by univariate and multivariate logistic regression analyses.Results: The incidence of overall reactions was 0.45% (48/10,595); 45 reactions were mild and three were moderate. No severe reactions were observed. Although the incidence of adverse reactions did not differ significantly between male and female patients, younger individuals were at higher risk for acute adverse reactions. The contrast injection rate and contrast dose were not significantly related to the incidence of adverse reactions. The incidence of adverse reactions was significantly higher for gadoxetate disodium (0.82%) than gadopentetate dimeglumine (0.43%).Conclusion: The incidence of acute adverse reactions elicited by Gd-based contrast agents injection was only 0.45%. Younger age was a risk factor for acute reactions. All 4 agents were found to be safe, although gadoxetate disodium showed a relatively higher incidence of adverse reactions.

show abstract

“…The transmetallation of gadolinium with endogenous metal ions such as copper and zinc is less common in cyclic chelates than acyclic chelates [19]. For the clinical agents, the LD 50 falls into a range of 8-15 mmol kg −1 [20][21][22], and reported adverse effects for these Gd-based contrast agents are rare [23][24][25].…”

Section: Introductionmentioning

confidence: 99%

Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging

Chan

Wong

2007

Coordination Chemistry Reviews

168

118

View full text Add to dashboard Cite

Safety of MR liver specific contrast media

Cited by 42 publications

References 48 publications

The T2-Shortening Effect of Gadolinium and the Optimal Conditions for Maximizing the CNR for Evaluating the Biliary System: a Phantom Study

The T2-Shortening Effect of Gadolinium and the Optimal Conditions for Maximizing the CNR for Evaluating the Biliary System: a Phantom Study

Incidence and Severity of Acute Adverse Reactions to Four Different Gadolinium-based MR Contrast Agents

Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging

Contact Info

Product

Resources

About